Lallemand signs agreement for exclusive use of Aventus’ NutraJIT for probiotics

Lallemand Health Solutions signed a global agreement with Aventus Innovations granting Lallemand exclusive use of NutraJIT, a patented, all-natural oral delivery platform, for probiotic applications.

Lallemand Health Solutions (Mirabel, Canada) signed a global agreement with Aventus Innovations granting Lallemand exclusive use of NutraJIT, a patented, all-natural oral delivery platform, for probiotic applications. The platform offers a combination of gastric protection and controlled release.

“This protective technology is efficient on both capsules and tablets, which is a great addition to our existing portfolio,” said Marie-Eve Boyte, scientific affairs director at Lallemand Health Solutions, in a press release. “NutraJIT is a versatile vehicle for active ingredients to make their way to their site of action, without being affected by the stomach fluids’ acidity and with reduced gastric side effects.”

According to Bérengère Feuz, marketing director at Lallemand Health Solutions, NutraJIT is a derivative of food-product protein, so it’s allergen-free and clean-label. “Even though we have existing protective technologies to make sure all our probiotic strains reach their site of action, NutraJIT brings its own additional benefits for consumers,” Feuz said. “Basically, the ingredient creates a gel barrier in a low pH environment, protecting the probiotic formula from stomach acidity. When reaching the intestines, it will desegregate as the pH is increasing, releasing the bacteria where they need to be. We are eager to bring this new attractive solution to the probiotic market and are actively preparing the launch for the coming fall.”